The GLP-1 market is projected to reach $200 billion globally by 2030, with 25 million Americans on treatment, driven by reduced prices, Medicare/Medicaid coverage, and oral formulations approved in late 2025.1
Oral GLP-1 pills from Novo Nordisk (launched early 2026) and Eli Lilly (expected Q2 2026) eliminate cold-chain needs, boosting global access and utilization.1
Eli Lilly surpassed $1 trillion market cap due to GLP-1 demand; Pfizer acquired Metsera for $10 billion in 2025 for incretin assets.12
Insurance expansions, including Medicare for obesity and WHO guidelines recognizing obesity as chronic, accelerate market penetration.125
GLP-1s expand beyond weight loss to cardiovascular benefits, MASH treatment (semaglutide approved), and pipelines like CagriSema and amycretin.23
Growth impacts industries:
$30–$55 billion annual revenue hit to food/beverage by 2030–2034 from reduced calorie intake.1
Sources:
1. https://www.jpmorgan.com/insights/global-research/current-events/obesity-drugs
2. https://www.iqvia.com/locations/emea/blogs/2026/01/outlook-for-obesity-in-2026
3. https://news.harvard.edu/gazette/story/2026/02/whats-next-for-glp-1s/
5. https://www.mmm-online.com/news/2026-is-the-year-glp-1s-grow-up/